AP1465A - Gardos channel antagonists. - Google Patents

Gardos channel antagonists.

Info

Publication number
AP1465A
AP1465A APAP/P/2001/002268A AP2001002268A AP1465A AP 1465 A AP1465 A AP 1465A AP 2001002268 A AP2001002268 A AP 2001002268A AP 1465 A AP1465 A AP 1465A
Authority
AP
ARIPO
Prior art keywords
channel antagonists
gardos channel
potassium flux
inhibitors
suprising
Prior art date
Application number
APAP/P/2001/002268A
Other languages
English (en)
Other versions
AP2001002268A0 (en
Inventor
Grant Andrew Mcnaughton-Smith
Gregory Cooksey Rigdon
Jonathan Walter Stocker
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of AP2001002268A0 publication Critical patent/AP2001002268A0/xx
Application granted granted Critical
Publication of AP1465A publication Critical patent/AP1465A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
APAP/P/2001/002268A 1999-02-23 2000-02-10 Gardos channel antagonists. AP1465A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13551199P 1999-02-23 1999-02-23
US09/386,601 US6288122B1 (en) 1999-02-23 1999-08-31 Gardos channel antagonists
PCT/US2000/003663 WO2000050026A1 (en) 1999-02-23 2000-02-10 Gardos channel antagonists

Publications (2)

Publication Number Publication Date
AP2001002268A0 AP2001002268A0 (en) 2001-09-30
AP1465A true AP1465A (en) 2005-09-22

Family

ID=26833406

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002268A AP1465A (en) 1999-02-23 2000-02-10 Gardos channel antagonists.

Country Status (16)

Country Link
US (1) US6288122B1 (2)
EP (1) EP1158971B1 (2)
JP (2) JP4038337B2 (2)
KR (1) KR100705726B1 (2)
CN (1) CN1193748C (2)
AP (1) AP1465A (2)
AT (1) ATE370728T1 (2)
AU (1) AU762039B2 (2)
BR (1) BR0008416A (2)
CA (1) CA2371857C (2)
DE (1) DE60036093T2 (2)
ES (1) ES2291191T3 (2)
HK (1) HK1045262B (2)
IL (2) IL145012A0 (2)
OA (1) OA11838A (2)
WO (1) WO2000050026A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
EP1465863B1 (en) 2002-01-04 2008-07-09 NeuroSearch A/S Potassium channel modulators
AU2003217810C9 (en) * 2002-02-28 2008-06-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
WO2005003143A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Novel potassium channel modulators
WO2005003094A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Diarylmethyl derivatives as potassium channel modulators
WO2006084031A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
EP1968563A4 (en) * 2005-12-20 2010-05-19 Icagen Inc TREATMENT METHODS USING TRIARYLMETHANE COMPOUNDS
PT2192896E (pt) 2007-08-24 2011-04-04 Neurosearch As Derivados de carbonilamino úteis para o tratamento de doença inflamatória intestinal
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
EA023596B1 (ru) 2008-04-09 2016-06-30 Сирус Корпорейшн Способы обработки композиции эритроцитов для инактивации патогена
EP2358750B1 (en) 2008-11-10 2017-01-11 Boehringer Ingelheim International GmbH Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
WO2016134353A1 (en) * 2015-02-20 2016-08-25 Children's Medical Center Corporation Methods for treating malaria using potassium channel inhibitors
EP3106155A1 (en) 2015-06-15 2016-12-21 Universite d'Aix Marseille Treatment and diagnosis of hereditary xerocytosis
AU2017350760B2 (en) * 2016-10-25 2022-03-31 Paracelsus Neuroscience I, LIc Use of senicapoc for treatment of neuropathic pain
WO2018162426A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment and diagnosis of hereditary xerocytosis
WO2020198939A1 (zh) * 2019-03-29 2020-10-08 深圳仁泰医药科技有限公司 2,2-双(4-氟苯基)-2-苯乙酰胺的晶型a及其制备方法和应用
US12186286B2 (en) * 2019-07-29 2025-01-07 Paracelsus Neuroscience Llc Use of senicapoc for treatment of stroke
CN115943138A (zh) * 2020-07-14 2023-04-07 阿迪玛生物有限责任公司 包含gardos通道拮抗剂的组合物及其用途
CA3201648A1 (en) * 2020-12-11 2022-06-16 Robin VAN BRUGGEN Treatment and prevention of anaemia of inflammation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034589A1 (en) * 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034589A1 (en) * 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease

Also Published As

Publication number Publication date
JP4038337B2 (ja) 2008-01-23
DE60036093T2 (de) 2008-05-15
IL145012A0 (en) 2002-06-30
KR100705726B1 (ko) 2007-04-11
AU2880700A (en) 2000-09-14
JP2007262075A (ja) 2007-10-11
AU762039B2 (en) 2003-06-19
EP1158971A4 (en) 2003-04-16
IL145012A (en) 2006-12-10
AP2001002268A0 (en) 2001-09-30
US6288122B1 (en) 2001-09-11
BR0008416A (pt) 2002-01-29
CA2371857A1 (en) 2000-08-31
OA11838A (en) 2005-08-22
WO2000050026A1 (en) 2000-08-31
EP1158971A1 (en) 2001-12-05
CN1344158A (zh) 2002-04-10
CN1193748C (zh) 2005-03-23
ATE370728T1 (de) 2007-09-15
HK1045262A1 (en) 2002-11-22
DE60036093D1 (de) 2007-10-04
ES2291191T3 (es) 2008-03-01
HK1045262B (zh) 2005-07-29
EP1158971B1 (en) 2007-08-22
KR20020002393A (ko) 2002-01-09
CA2371857C (en) 2008-07-29
JP2002537331A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
AP1465A (en) Gardos channel antagonists.
GEP20084461B (en) New derivative of 3,3- diphenyl-propylamine
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
GB9818916D0 (en) Use
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
NO20010309D0 (no) Ikke-peptidiske midler for inhibering av gonatropinfrigjörende hormoner, samt fremgangsmåter og mellomprodukter til fremstilling derav
PL338352A1 (en) Derivatives of 1-(n-phenylaminoalkyl)-piperazine substituted at position 2 of its phenyl ring
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
MXPA05009694A (es) Metodos para mejorar la calidad de la piel.
WO2000056774A8 (en) Methods of using bioelastomers
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
DE60105401D1 (de) Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit
DE60019586D1 (de) Myostatin genpromoter und inhibierung dessen aktivierung
EA200401622A1 (ru) Способы лечения ангиогенеза, роста опухолей и метастазов
ATE304866T1 (de) Chelatorkonjugate mit verbesserten eigenschaften
AU6769801A (en) Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
WO2003066885A3 (en) Method for screening for compounds having hdac inhibitory activity
AU2003215381A8 (en) Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer
NO20006699D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
NO20012719D0 (no) Preparat med forbedret terapeutisk bredde, inneholdende nukleotidsynteseinhibitorer
AU2002214657A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
EA200400764A1 (ru) 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper